Virtual Machine Status Probe Method, and Device

A virtual machine status probe method includes obtaining an invocation message and an identifier of a first virtual machine, invoking a probe script based on the invocation message, and transferring the identifier of the first virtual machine to the probe script, sending a probe packet to a source device by running the probe script, receiving feedback information sent by the source device, where the feedback information is used to indicate the status of the first virtual machine, and determining, based on the feedback information, whether to recreate the first virtual machine in the destination device. 1. A virtual machine status probe method implemented by a destination device , comprising:obtaining an invocation message and a first identifier of a first virtual machine;invoking a probe script based on the invocation message;transferring the first identifier to the probe script;sending a probe packet by running the probe script, wherein the probe packet probes a status of the first virtual machine in a source device, and wherein the probe packet comprises the first identifier;receiving feedback information from the source device in response to the probe packet, wherein the feedback information indicates the status; anddetermining, based on the feedback information, whether to recreate the first virtual machine in the destination device.2. The virtual machine status probe method of claim 1 , wherein the probe packet is a broadcast packet when a first probe port of the source device and a second probe port of the destination device are located in a same virtual local area network (VLAN) claim 1 , and wherein the probe packet comprises a probe VLAN identifier of a first service plane in which the first virtual machine is located.3. The virtual machine status probe method of claim 2 , further comprising:receiving the probe VLAN identifier from a management device;configuring the second probe port in the first service plane;configuring the probe VLAN identifier for the ...

Pyridone Derivative, Composition and Use as Antiviral Drug Thereof

The present disclosure belongs to the field of medicinal chemistry, and relates to a novel pyridone derivative represented by Formula (I) or a stereoisomer, a pharmaceutically acceptable salt, a solvate or a crystal thereof, and use thereof in the preparation of a drug for preventing or treating diseases such as influenza type A viral infection and/or influenza type B viral infection, particularly use thereof as a PA subunit cap-dependent endonuclease inhibitor for preventing or treating diseases such as influenza type A viral infection and/or influenza type B viral infection. The compounds of the present disclosure have significant activity in inhibiting influenza endonuclease and influenza DNA, can be used either alone or in combination with a neuraminidase inhibitor, a nucleoside drug, a PB2 inhibitor, a PB1 inhibitor, an M2 inhibitor or other anti-influenza drugs, significantly shorten the time of influenza infection and reduces mortality, and have excellent clinical application prospects. 3. The pyridone derivative or the stereoisomer claim 1 , the pharmaceutically acceptable salt claim 1 , the solvate or the crystal thereof according to claim 1 , wherein claim 1 , in the heterocyclic ring or the heteroaromatic ring claim 1 , a heteroatom is dependently selected from N claim 1 , O claim 1 , or S.4. (canceled)5. The pyridone derivative or the stereoisomer claim 1 , the pharmaceutically acceptable salt claim 1 , the solvate or the crystal thereof according to claim 1 , wherein W is selected from the following groups:{'sub': 8', '2', '8', '2', '8', '2', '8', '2', '8', '2', '8', '3', '8', '3', '2', '8', '2', '2', '2', '8', '2', '2', '8', '2', '8', '1-6', '1-6', '1-6', '1-6', '1-6', '1-6', '1-6', '1-6', '1-6', '1-6', '3-6', '3-6', '3-6', '3-6', '3-6', '3-6', '3-6', '3-6', '4-8', '4-8', '4-8', '4-8', '4-8', '4-8', '5-10', '5-10', '5-10', '5-10', '5-10', '5-10', '1-6', '1-6', '3-6', '3-6', '5-10', '5-10', '5-10', '5-10, '(a) —C(═O)—R; (b) —C(═O)—(CH)k-R, k is selected ...

ISOQUINOLINONE COMPOUNDS AND USE THEREOF IN PREPARATION OF ANTIVIRAL DRUGS

Disclosed is an isoquinolinone compound as shown in Formula (I) or a stereoisomer, pharmaceutically acceptable salt, solvate or crystal thereof, and a preparation method thereof, and use thereof in the preparation of drugs for treating or preventing viral infectious diseases caused by the hepatitis B virus (HBV) and other viruses, in particular, use thereof in drugs as HBV surface antigen inhibitors and HBV DNA production inhibitors. The compound has a significant activity in inhibiting hepatitis B surface antigen and hepatitis B DNA, and is possible to significantly improve the probability of curing hepatitis B by administration in combination with nucleoside drugs or other drugs in the future, and has good clinical application prospects. 119.-. (canceled)21. The isoquinolinone compound or the stereoisomer claim 20 , the pharmaceutically acceptable salt claim 20 , the solvate or the crystal thereof according to wherein claim 20 , Ris R—O— claim 20 , wherein Ris selected from Ccycloalkyl; Cbicycloalkyl; deuterated Calkyl; Cheterocycloalkyl; Calkyl carbonyl Calkyl; deuterated CalkoxyCalkyl; Calkoxy Ccycloalkyl; Calkoxy Ccycloalkyl Calkyl; Cheterocycloalkyl; Calkoxy Calkyl claim 20 , wherein alkyl is substituted by Ccycloalkyl or Cheterocycloalkyl claim 20 , and a heteroatom in heterocycloalkyl is selected from oxygen claim 20 , sulphur or nitrogen; when Ris selected from Calkoxy Calkyl claim 20 , Rand R′ are independently selected from deuterium claim 20 , fluorine claim 20 , chlorine claim 20 , hydroxyl and cyano claim 20 , and W is N or CR claim 20 , wherein Ris selected from deuterium claim 20 , fluorine claim 20 , chlorine claim 20 , hydroxyl claim 20 , and cyano.22. The isoquinolinone compound or the stereoisomer claim 20 , the pharmaceutically acceptable salt claim 20 , the solvate or the crystal thereof according to wherein claim 20 , Ris selected from Ccycloalkoxy claim 20 , Cheterocycloalkyloxy claim 20 , Calkoxy Ccycloalkoxy claim 20 , Calkoxy Ccycloalkyl ...

Track support assembly for track transfer device

本实用新型公开了一种用于变轨装置的轨道支架组件，包括支架主体、轨道调节机构和外围轨道组件；所述外围轨道组件包括至少两组外围轨道，每组外围轨道包括一根外围轨道或者两根间隔且在同一直线上的外围轨道，各组外围轨道之间相互平行；每个所述外围轨道通过轨道调节机构与所述支架主体相连接。该轨道支架组件结构稳固，体积小，由于在变轨部分采用多根平行的轨道，可以实现三根以上的轨道的变轨切换，此外整体刚度强，形变小，行走过程稳定性好，轨道调节和维护方便，使用寿命长。

Pyridone derivative, composition thereof and application thereof as anti-influenza drug

The present invention relates to the field of medical chemistry, and relates to a novel pyridone derivative represented by formula (I) or a stereoisomer thereof, a pharmaceutically acceptable salt, a solvate or a crystal thereof, and an application thereof in the preparation of a drug for preventing or treating viral infectious diseases such as influenza A or/and influenza B, in particular an application thereof as a PA subunit cap-dependent endonuclease inhibitor for preventing or treating influenza A and/or influenza B viral infectious diseases. The compound of the present invention has significant activity in inhibiting influenza endonuclease and influenza DNA, and may be used alone or in combination with a neuraminidase inhibitor, a nucleoside drug, a PB2 inhibitor, a PB1 inhibitor, an M2 inhibitor or other anti-influenza drugs, significantly shortening the time of influenza infection, reducing mortality, and having excellent clinical application prospects.

Pyridone derivative, composition thereof and application thereof as anti-influenza drug

Isoquinolinone compound and use thereof in preparation of antiviral drugs

Disclosed is an isoquinolinone compound as shown in Formula (I) or a stereoisomer, pharmaceutically acceptable salt, solvate or crystal thereof, and a preparation method thereof, and use thereof in the preparation of drugs for treating or preventing viral infectious diseases caused by the hepatitis B virus (HBV) and other viruses, in particular, use thereof in drugs as HBV surface antigen inhibitors and HBV DNA production inhibitors. The compound has a significant activity in inhibiting hepatitis B surface antigen and hepatitis B DNA, and is possible to significantly improve the probability of curing hepatitis B by administration in combination with nucleoside drugs or other drugs in the future, and has good clinical application prospects.

Robotic cleaner

Formulations of human parathyroid hormone (pth) and methods for producing same

Isoquinolinone compound and use thereof in preparation of antiviral drugs

Disclosed is an isoquinolinone compound as shown in formula (I) or a stereoisomer, pharmaceutically acceptable salt, solvate or crystal thereof, and a preparation thereof and a use thereof in the preparation of drugs for treating or preventing viral infectious diseases caused by the hepatitis B virus (HBV) and other viruses, in particular, a use thereof in drugs for HBV Surface antigen inhibitors and HBV DNA production inhibitors. The compound has a significant activity for inhibiting the hepatitis B surface antigen and hepatitis B DNA, and it is possible to significantly improve the probability of curing hepatitis B by administration of same in combination with nucleoside drugs or other drugs in the future, and same has good clinical application prospects.

Suction device

Pyridone derivative, composition and use as antiviral drug thereof

The present disclosure relates to a pyridone derivative represented by Formula (I) or a stereoisomer, a pharmaceutically acceptable salt, a solvate or a crystal thereof, and use thereof in the preparation of a drug for preventing or treating diseases such as influenza type A viral infection and/or influenza type B viral infection. In Formula (I), Re and R are connected and form a sixth ring together with a nitrogen atom both connected therewith, and the sixth ring is a spiro ring, a ring in the spiro ring that shares the nitrogen atom with a parent ring has an oxygen or nitrogen atom at a position opposite to the nitrogen atom. Compared to known compounds, compounds of the present disclosure have more significant activity in inhibiting influenza endonuclease and influenza DNA, may significantly shorten the time of influenza infection and reduce mortality, and have excellent clinical application prospects.

Device for online co-production of carbon-containing precursors and high-quality oxygen-containing fuels from biomass pyrolysis gas

A device for online co-production of carbon-containing precursors and high-quality oxygen-containing fuels from biomass pyrolysis gas includes a spray polymerization reactor, where a biomass pyrolysis gas inlet and a polymerization agent inlet are provided on the spray polymerization reactor, an outlet of the spray polymerization reactor is connected to an inlet of a catalytic reactor, and an outlet of the catalytic reactor is connected to an inlet of a condenser; a spray pipe is arranged at a top in the spray polymerization reactor, and a detachable collector for collecting the carbon-containing precursors is mounted at a bottom of the spray polymerization reactor; and a catalyst is arranged in the catalytic reactor, such that micromolecular pyrolysis gas is catalytically converted into the high-quality oxygen-containing fuels.

Virtual machine status probe method, and device

A virtual machine status probe method includes obtaining an invocation message and an identifier of a first virtual machine, invoking a probe script based on the invocation message, and transferring the identifier of the first virtual machine to the probe script, sending a probe packet to a source device by running the probe script, receiving feedback information sent by the source device, where the feedback information is used to indicate the status of the first virtual machine, and determining, based on the feedback information, whether to recreate the first virtual machine in the destination device.

Frequency domain-based method for removing periodic noise from reconstructed light field image

A method for removing periodic noise from a reconstructed light field image includes the steps of: acquiring a light field image of a sample; acquiring an optical center position map without the sample; calibrating the imaging centers of the microlenses and performing reconstruction on the light field image; transforming a reconstructed light field image to the frequency domain and generating an image frequency spectrum; preprocessing the image frequency spectrum; generating a low-pass filter; multiplying the low-pass filter with the preprocessed image frequency spectrum, and then setting the frequency spectrum value of the low-frequency component to zero; performing binarization on the reconstructed light field image frequency spectrum to obtain an image mask; removing the high-frequency periodic noise component from the original frequency spectrum of the reconstructed light field image; and transforming the filtered reconstructed light field image frequency spectrum back to the spatial domain to obtain the reconstructed light field image.

Method and device for detecting state of virtual machine

Method and device for detecting state of virtual machine

This application provides a virtual machine status probe method and a device, to improve reliability of probing whether a virtual machine is faulty in the source device, thereby effectively avoiding occurrence of a virtual machine split brain. The method includes: obtaining an invocation message, where the invocation message is used to probe a first virtual machine; obtaining an identifier of the first virtual machine; invoking a probe script based on the invocation message, and transferring the identifier of the first virtual machine to the probe script; sending a probe packet by running the probe script, where the probe packet is used to probe a status of the first virtual machine in the source device, and the probe packet includes the identifier of the first virtual machine; receiving feedback information sent by the source device, where the feedback information is used to indicate the status of the first virtual machine; and determining, based on the feedback information, whether to recreate the first virtual machine in the destination device.

Antenna configuration parameter optimization method and apparatus, and storage medium

Embodiments of this application provide an antenna configuration parameter optimization method and apparatus, and a storage medium. The method includes: performing incremental update on a first prediction model based on a first antenna configuration parameter corresponding to an optimization region and a score of the first antenna configuration parameter, to obtain a second prediction model; obtaining a second antenna configuration parameter based on the second prediction model; determining whether to use the second antenna configuration parameter as a first target configuration parameter; and if the second antenna configuration parameter is used as the first target configuration parameter, delivering the second antenna configuration parameter. Incremental update is performed on the first prediction model based on the first antenna configuration parameter and the score of the first antenna configuration parameter, to obtain a new antenna configuration parameter based on an updated prediction model. According to the method, an updated prediction model can be quickly converged to an antenna configuration parameter with a higher score, so that efficiency of optimizing an antenna configuration parameter is improved.

Lung nodule screening method and screening system based on deep learning technology

Antenna configuration parameter optimization method and apparatus, and storage medium

Hydroponic culture method of sympodial bamboo

Elisa detection kit and detection method for iga antibody against porcine rotavirus group a

This invention provides an ELISA detection kit and method for IgA antibody against Porcine rotavirus group A, belonging to the field of animal husbandry detection technology. The ELISA detection method of this invention utilizes popular PoRV variant strains as parental strains to successfully express recombinant VP6 fusion protein in vitro. Subsequently, the VP6 fusion protein was used as an antigen to be coated onto enzyme-labeled plate to establish a novel ELISA detection method. The method provided by this invention possesses strong sensitivity, high specificity, robust stability, good reproducibility, and ease of preparation, and holds important clinical practical significance for the diagnosis, prevention and control of PoRV.

Base station energy-saving method and apparatus

Embodiments of this application provide a base station energy saving method and apparatus applied to the field of communication technologies. The method includes: determining, for one or more low-energy-efficiency cells in a low-energy-efficiency cell set, a high-energy-efficiency cell paired with each low-energy-efficiency cell from a high-energy-efficiency cell set, where a coverage area of the low-energy-efficiency cell partially overlaps a coverage area of the high-energy-efficiency cell paired with the low-energy-efficiency cell, and energy efficiency of a cell in the low-energy-efficiency cell set is lower than energy efficiency of a cell in the high-energy-efficiency cell set; and sending indication information to a base station of the low-energy-efficiency cell or a management network element configured to manage the low-energy-efficiency cell, where the indication information indicates to hand over user equipment in the low-energy-efficiency cell to the high-energy-efficiency cell paired with the low-energy-efficiency cell. According to embodiments of this application, the user equipment in the low-energy-efficiency cell may be handed over to the high-energy-efficiency cell paired with the low-energy-efficiency cell, to improve energy saving efficiency of the base station.

Base Station Energy Saving Method and Apparatus

A base station energy saving method includes: determining, for one or more low-energy-efficiency cells in a low-energy-efficiency cell set, a high-energy-efficiency cell paired with each low-energy-efficiency cell from a high-energy-efficiency cell set, where a coverage area of the low-energy-efficiency cell partially overlaps a coverage area of the high-energy-efficiency cell paired with the low-energy-efficiency cell, and energy efficiency of a cell in the low-energy-efficiency cell set is lower than energy efficiency of a cell in the high-energy-efficiency cell set; and sending indication information to a base station of the low-energy-efficiency cell or a management network element configured to manage the low-energy-efficiency cell. The user equipment in the low-energy-efficiency cell may be handed over to the high-energy-efficiency cell paired with the low-energy-efficiency cell.

Watch